Progressing towards reduction of the acute leukaemias impact at Dickins Group

23 June

After more than five years as a veski innovation fellow in the molecular medicine division of The Walter & Eliza Hall Institute of Medical Research, Associate Professor Ross Dickins has made a prestigious move and is now a group leader at The Australian Centre for Blood Diseases, a Monash University department located at the Alfred Hospital in Melbourne.

With the set-up of a new lab, Dickins Group, Ross and his team will research the tumour suppressor gene function, focusing on several hematopoietic transcription factors recurrently mutated in acute lymphoblastic and acute myeloid leukaemias (ALL and AML). The research into why the loss of particular genes in leukaemias causes treatment resistance, conducted by Ross and his team, is vital to the development of future therapies for difficult to treat leukaemia subtypes.

The laboratory is funded by the National Health and Medical Research Council (NHMRC), the Leukaemia Foundation of Australia, and the Sylvia and Charles Viertel Charitable Foundation.

veski innovation fellow Ross and his team are progressing towards reduction of the acute leukaemias impact: acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML).

Ross has also been awarded an Associate Professorship at Monash University.

What's On

S M T W T F S
 
 
 
 
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
11
 
12
 
13
 
14
 
15
 
16
 
17
 
18
 
19
 
20
 
21
 
22
 
23
 
24
 
25
 
26
 
27
 
28
 
29
 
30